Last checked at 
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday not separately reported by Alliance News:
----------
Seraphine Group PLC - London-based maternity wear retailer - Announces the offer for the company from Mayfair Equity Partners will close for acceptance at 1300 GMT on April 6. Urges shareholders who have not yet accepted the offer to do so as soon as possible. Confirms anticipated date of cancellation of the listing and admission to trading of Seraphine shares is expected to be on, or around, April 6. Notes Mayfair held 88% of Seraphine shares as at 1300GMT on March 22.
----------
SulNOx Group PLC - London-based green technology company - Announces that Chief Executive Officer Ben Richardson, is stepping down from the board with effect from today. Adds decision is being taken so Richardson can focus his efforts on sales and business development. He will remain in a non-board executive management position.
----------
Fragrant Prosperity Holdings Ltd - British Virgin Islands-based special purpose acquisition company - Signs heads of terms with Hi 55 Ventures Ltd, a UK based fintech business, in relation to the potential refinancing of FPH and acquisition of Hi 55 by FPH for GBP47 million. The acquisition, if it proceeds, will constitute a reverse takeover under the listing rules. Deal will be satisfied by the issue of shares in FPH. Requests suspension of shares. Oscillate PLC says Thursday it ended discussions to acquire Hi 55 Ventures. It says it will provide a more detailed update, including a timetable for lifting suspension of trading in its shares, shortly.
----------
Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical group developing new therapies and treatments for deadly blood diseases - Announces successful completion of a full set of analytical tests for HEMO-CAR-T. The completion of the tests is the last manufacturing requirement that is necessary for the submission of an investigational new drug application to the US Food & Drug Administration which is now being prepared. The IND is needed to obtain authorization from the FDA to commence Phase I clinical trials of HEMO-CAR-T.
----------
Macaulay Capital PLC - London-based private capital specialist - Raises GBP1.6 million to be invested in HC 1340 Ltd, a newco vehicle used to acquire an established engineering business. The investment is represented by GBP52,667 in ordinary shares for 52.7% of the equity, alongside GBP1.5 million in unsecured loan notes. The loan notes are scheduled to be redeemed in March 2029. Of the GBP1.6 million, the company has invested GBP700,000, which is higher than the anticipated GBP200,000 referred in its admission document. This enables the firm to complete the transaction within the agreed exclusivity period.
----------
Rockhopper Exploration plc - Salisbury, England-based oil & gas exploration and production company - Updates on Sea Lion development. Says new approach represents a material reduction in both upfront and life of field cost when compared to the previous development scheme, while still achieving a plateau production rate in the initial stage of approximately 80,000 bbls/d, a peak production rate of approximately 100,000 bbls/d. The new development plan proposes 18 wells to be drilled in phase 1, 11 of these coming before first oil. The phase 2 drilling campaign will add a further five wells approximately 42 months after first oil. Those later wells will also be tied into the FPSO to extend the production plateau.
By Jeremy Cutler, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
